Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from TruScreen Group Ltd. ( (AU:TRU) ) is now available.
TruScreen Group has been validated as a superior primary cervical cancer screening tool in a landmark clinical study by the Chinese Obstetricians and Gynaecologists Association, covering 14,982 women across 64 hospitals in nine provinces. The study, published in BMC Cancer, found TruScreen’s opto-electronic test offered higher sensitivity and negative predictive values than liquid-based cytology and performance comparable to HPV DNA testing for detecting severe precancerous lesions.
The publication strengthens TruScreen’s standing in China, where it is already referenced in national cervical screening guidelines, and is expected to drive its deeper inclusion in future CSCCP and COGA updates. With global screening coverage still far below World Health Organization targets, the results support TruScreen’s positioning as a practical solution for large public screening programs, particularly in low- and middle-income countries with limited laboratory infrastructure.
More about TruScreen Group Ltd.
TruScreen Group Ltd. is a global medical technology company focused on AI-enabled cervical cancer screening devices. Its opto-electronic TruScreen system targets large-scale screening needs, with China as its largest market and particular emphasis on emerging markets that lack extensive pathology infrastructure.
Average Trading Volume: 336,255
Technical Sentiment Signal: Hold
Current Market Cap: A$11.48M
For detailed information about TRU stock, go to TipRanks’ Stock Analysis page.